Tumor Targeting Articles & Analysis
48 articles found
This system allows researchers to target specific DNA sequences within a genome, facilitating the addition, removal, or alteration of genetic information. ...
Antibody-drug conjugates (ADCs) combine potent small-molecule drugs with monoclonal antibodies for targeted cancer therapy. A major challenge is loading enough drug onto each antibody without compromising solubility or circulation time. ...
Additionally, PEGylation protects proteins from aggregation and denaturation, improving shelf-life. 4. Enhanced Tumor Targeting (Passive Accumulation) In oncology, PEGylated drugs benefit from the Enhanced Permeability and Retention (EPR) effect, where leaky tumor vasculature allows selective accumulation of macromolecules. ...
The complex nature of cancer treatment highlights the critical requirement for therapies that show both effectiveness and precise targeting of tumor biology. The conventional treatment approaches fail to accurately target cancer cells, which results in numerous adverse effects while diminishing treatment success. FAP-targeted ...
Traditional cancer treatments do not possess the necessary precision to target only cancer cells which leads to poor treatment results and harmful side effects. ...
The monoclonal antibody is designed to bind specifically to cancer cells, ensuring that the toxic drug is delivered directly to the tumor, thereby minimizing damage to healthy cells. This targeted approach enhances the therapeutic index of the drug, resulting in improved efficacy and reduced side effects compared to conventional chemotherapy. ...
Watertown, MA – March 24, 2025 – Biopharma PEG, a leading supplier of high-quality polyethylene glycol (PEG) derivatives, highlights its innovative product DSPE-PEG-Mannose, an advanced biomedical polymer with significant potential in drug delivery, tumor-targeted therapy, tissue recognition, and adhesion.Structural Advantages of DSPE-PEG-MannoseDSPE-PEG-Mannose ...
Unlike traditional cancer therapies that often target the tumor directly, these services aim to empower the immune system to recognize and attack cancer more effectively. ...
These advancements not only enhance our understanding of the disease but also pave the way for more targeted therapeutic solutions. Tumor models for breast cancer, which include both in vivo and in vitro systems, are crucial for studying the complexities of tumor biology and testing potential treatments. ...
Compared with traditional cytotoxins, ADCs have the advantages of strong targeting, less toxic side effects, etc. They can accurately target tumor cells, reduce side effects, and improve the therapeutic effect.ADC drugs are mainly composed of monoclonal antibodies, linkers, and small molecule cytotoxins. ...
Kate Sasser from Tempus led a discussion on the potential of antibody-drug conjugates (ADCs), their challenges in targeting tumor antigens, and the future of cancer treatment with Dr. Daniel Johnson, Dr. ...
ByTempus
Since the FDA approved the first oral small molecule targeted therapy for tumors-tamoxifen targeting the estrogen receptor (ER)-in 1977 for the treatment of breast cancer, small molecule drug development has typically focused on screening for high-affinity inhibitors. ...
The purpose of DAC is to treat diseases by targeting and degrading pathological proteins, such as degrading key proteins on the surface of tumor cells in cancer treatment.Common Features of SMDC, ADC, and DACSMDC, ADC, and DAC all utilize advanced structure optimization techniques, combining the active ingredients of drugs with targeted ...
The clinical research targets of nanobodies used for molecular diagnosis include HER2, HER3, PD-L1, AlbudAb, CD20, CD38, CD8, CEA and HGF, etc., mainly involving the field of tumor targeted diagnosis.Nanobodies for Disease TreatmentCamelid IgG antibodies are highly homologous to human IgG, and their immunogenicity can be reduced through nanobody ...
Conventional liposomes As a drug delivery system, traditional liposomes can change the pharmacokinetic properties and tissue distribution of tumor drugs, enhance the target aggregation concentration of drugs, and enhance drug efficacy. However, traditional liposomes still have shortcomings such as unsatisfactory targeting distribution ...
Benefits of fluorescent liposomes Real-time tracking: Researchers can observe the movement of liposomes within tissues and organs, understanding their uptake by cells, biodistribution, and potential off-target effects. Drug delivery optimization: By watching how liposomes interact with different cell types, scientists can fine-tune their design and targeting ...
They may also be quickly degraded or eliminated before reaching their target. Liposomes offer several advantages: Targeted delivery: Liposomes can be modified with targeting ligands, like antibodies, that bind to specific receptors on diseased cells. ...
They are essentially ADC drugs. NIR-PIT drugs can form a new targeted anti-tumor platform that irradiates infrared light to the tumor site through the device. ...
The high specificity of bispecific antibodies enables more precise targeting of tumor cells. On the other hand, promoting the coordinated endocytosis of the two targets through cross-linking can improve the efficiency of toxins entering tumor cells. ...
The above several NF-κB-mediated cancer formation mechanisms can coordinate with each other and interact at different signaling levels to jointly promote tumorigenesis and progression. Currently, tumor-targeted therapy targeting NF-κB is one of the hot spots in cancer treatment. ...